Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 175

1.

Upregulation of miR-135b is involved in the impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients.

Xu S, Cecilia Santini G, De Veirman K, Vande Broek I, Leleu X, De Becker A, Van Camp B, Vanderkerken K, Van Riet I.

PLoS One. 2013 Nov 6;8(11):e79752. doi: 10.1371/journal.pone.0079752. eCollection 2013.

2.

Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.

Hu J, Van Valckenborgh E, Xu D, Menu E, De Raeve H, De Bruyne E, Xu S, Van Camp B, Handisides D, Hart CP, Vanderkerken K.

Mol Cancer Ther. 2013 Sep;12(9):1763-73. doi: 10.1158/1535-7163.MCT-13-0123. Epub 2013 Jul 5. Erratum in: Mol Cancer Ther. 2015 Jul;14(7):1762. De Bryune, Elke [Corrected to De Bruyne, Elke].

3.

Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo.

Xu S, De Veirman K, Evans H, Santini GC, Vande Broek I, Leleu X, De Becker A, Van Camp B, Croucher P, Vanderkerken K, Van Riet I.

Acta Pharmacol Sin. 2013 May;34(5):699-709. doi: 10.1038/aps.2012.182. Epub 2013 Apr 8.

4.

In vitro expanded bone marrow-derived murine (C57Bl/KaLwRij) mesenchymal stem cells can acquire CD34 expression and induce sarcoma formation in vivo.

Xu S, De Becker A, De Raeve H, Van Camp B, Vanderkerken K, Van Riet I.

Biochem Biophys Res Commun. 2012 Aug 3;424(3):391-7. doi: 10.1016/j.bbrc.2012.06.118. Epub 2012 Jul 6.

PMID:
22771324
5.

The HDAC inhibitor LBH589 enhances the antimyeloma effects of the IGF-1RTK inhibitor picropodophyllin.

Lemaire M, Fristedt C, Agarwal P, Menu E, Van Valckenborgh E, De Bruyne E, Österborg A, Atadja P, Larsson O, Axelson M, Van Camp B, Jernberg-Wiklund H, Vanderkerken K.

Clin Cancer Res. 2012 Apr 15;18(8):2230-9. doi: 10.1158/1078-0432.CCR-11-1764. Epub 2012 Mar 5.

6.

Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition.

Hu J, Dang N, Menu E, De Bruyne E, Xu D, Van Camp B, Van Valckenborgh E, Vanderkerken K.

Blood. 2012 Jan 19;119(3):826-37. doi: 10.1182/blood-2011-07-366492. Epub 2011 Nov 29. Erratum in: Blood. 2014 Jul 24;124(4):663. De Bryune, Elke [corrected to De Bruyne, Elke].

PMID:
22128141
7.

Bone marrow-derived mesenchymal stromal cells are attracted by multiple myeloma cell-produced chemokine CCL25 and favor myeloma cell growth in vitro and in vivo.

Xu S, Menu E, De Becker A, Van Camp B, Vanderkerken K, Van Riet I.

Stem Cells. 2012 Feb;30(2):266-79. doi: 10.1002/stem.787.

8.

Dll1/Notch activation accelerates multiple myeloma disease development by promoting CD138+ MM-cell proliferation.

Xu D, Hu J, Xu S, De Bruyne E, Menu E, Van Camp B, Vanderkerken K, Van Valckenborgh E.

Leukemia. 2012 Jun;26(6):1402-5. doi: 10.1038/leu.2011.332. Epub 2011 Nov 18. No abstract available.

PMID:
22094583
9.

An improved harvest and in vitro expansion protocol for murine bone marrow-derived mesenchymal stem cells.

Xu S, De Becker A, Van Camp B, Vanderkerken K, Van Riet I.

J Biomed Biotechnol. 2010;2010:105940. doi: 10.1155/2010/105940. Epub 2010 Dec 20.

10.

Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug.

Hu J, Handisides DR, Van Valckenborgh E, De Raeve H, Menu E, Vande Broek I, Liu Q, Sun JD, Van Camp B, Hart CP, Vanderkerken K.

Blood. 2010 Sep 2;116(9):1524-7. doi: 10.1182/blood-2010-02-269126. Epub 2010 Jun 7.

PMID:
20530289
11.

Thymosin β4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma.

Caers J, Hose D, Kuipers I, Bos TJ, Van Valckenborgh E, Menu E, De Bruyne E, Goldschmidt H, Van Camp B, Klein B, Vanderkerken K.

Haematologica. 2010 Jan;95(1):163-7. doi: 10.3324/haematol.2009.006411. Epub 2009 Oct 14.

12.

Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.

Deleu S, Lemaire M, Arts J, Menu E, Van Valckenborgh E, Vande Broek I, De Raeve H, Coulton L, Van Camp B, Croucher P, Vanderkerken K.

Cancer Res. 2009 Jul 1;69(13):5307-11. doi: 10.1158/0008-5472.CAN-08-4472. Epub 2009 Jun 16.

13.

The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models.

Deleu S, Lemaire M, Arts J, Menu E, Van Valckenborgh E, King P, Vande Broek I, De Raeve H, Van Camp B, Croucher P, Vanderkerken K.

Leukemia. 2009 Oct;23(10):1894-903. doi: 10.1038/leu.2009.121. Epub 2009 Jun 4.

PMID:
19494837
14.

The role of the insulin-like growth factor 1 receptor axis in multiple myeloma.

Menu E, van Valckenborgh E, van Camp B, Vanderkerken K.

Arch Physiol Biochem. 2009 May;115(2):49-57. doi: 10.1080/13813450902736583. Review.

PMID:
19234898
15.

Multiple myeloma--an update on diagnosis and treatment.

Caers J, Vande broek I, De Raeve H, Michaux L, Trullemans F, Schots R, Van Camp B, Vanderkerken K.

Eur J Haematol. 2008 Nov;81(5):329-43. doi: 10.1111/j.1600-0609.2008.01127.x. Epub 2008 Sep 13. Review.

PMID:
18637123
16.

Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma.

Caers J, Menu E, De Raeve H, Lepage D, Van Valckenborgh E, Van Camp B, Alvarez E, Vanderkerken K.

Br J Cancer. 2008 Jun 17;98(12):1966-74. doi: 10.1038/sj.bjc.6604388. Epub 2008 Jun 3.

17.

Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survival.

De Bruyne E, Bos TJ, Asosingh K, Vande Broek I, Menu E, Van Valckenborgh E, Atadja P, Coiteux V, Leleu X, Thielemans K, Van Camp B, Vanderkerken K, Van Riet I.

Clin Cancer Res. 2008 May 15;14(10):2918-26. doi: 10.1158/1078-0432.CCR-07-4489.

18.

Unraveling the biology of multiple myeloma disease: cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment.

Caers J, Van Valckenborgh E, Menu E, Van Camp B, Vanderkerken K.

Bull Cancer. 2008 Mar;95(3):301-13. doi: 10.1684/bdc.2008.0600. Review.

20.

Extravasation and homing mechanisms in multiple myeloma.

Vande Broek I, Vanderkerken K, Van Camp B, Van Riet I.

Clin Exp Metastasis. 2008;25(4):325-34. Epub 2007 Oct 19. Review.

PMID:
17952614
21.

Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival.

Menu E, Jernberg-Wiklund H, De Raeve H, De Leenheer E, Coulton L, Gallagher O, Van Valckenborgh E, Larsson O, Axelson M, Nilsson K, Van Camp B, Croucher P, Vanderkerken K.

Int J Cancer. 2007 Oct 15;121(8):1857-61.

22.

Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.

Vanderkerken K, Medicherla S, Coulton L, De Raeve H, Willems A, Lawson M, Van Camp B, Protter AA, Higgins LS, Menu E, Croucher PI.

Cancer Res. 2007 May 15;67(10):4572-7. Epub 2007 May 10.

23.

Neighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells.

Caers J, Deleu S, Belaid Z, De Raeve H, Van Valckenborgh E, De Bruyne E, Defresne MP, Van Riet I, Van Camp B, Vanderkerken K.

Leukemia. 2007 Jul;21(7):1580-4. Epub 2007 Mar 22. No abstract available.

24.

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.

Edwards CM, Mueller G, Roelofs AJ, Chantry A, Perry M, Russell RG, Van Camp B, Guyon-Gellin Y, Niesor EJ, Bentzen CL, Vanderkerken K, Croucher PI.

Int J Cancer. 2007 Apr 15;120(8):1657-63.

25.

Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model.

Menu E, De Leenheer E, De Raeve H, Coulton L, Imanishi T, Miyashita K, Van Valckenborgh E, Van Riet I, Van Camp B, Horuk R, Croucher P, Vanderkerken K.

Clin Exp Metastasis. 2006;23(5-6):291-300. Epub 2006 Nov 3.

PMID:
17086356
26.

Endothelial cell-driven regulation of CD9 or motility-related protein-1 expression in multiple myeloma cells within the murine 5T33MM model and myeloma patients.

De Bruyne E, Andersen TL, De Raeve H, Van Valckenborgh E, Caers J, Van Camp B, Delaissé JM, Van Riet I, Vanderkerken K.

Leukemia. 2006 Oct;20(10):1870-9. Epub 2006 Aug 10.

27.

The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model.

Menu E, Asosingh K, Indraccolo S, De Raeve H, Van Riet I, Van Valckenborgh E, Vande Broek I, Fujii N, Tamamura H, Van Camp B, Vanderkerken K.

Haematologica. 2006 May;91(5):605-12. Epub 2006 Apr 19. Erratum in: Haematologica. 2007 Nov;92(11):1584. Van de Broek, Isabelle [corrected to Vande Broek, Isabelle].

28.

Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival.

Vande Broek I, Leleu X, Schots R, Facon T, Vanderkerken K, Van Camp B, Van Riet I.

Haematologica. 2006 Feb;91(2):200-6. Erratum in: Haematologica. 2007 Nov;92(11):1584. Van de Broek, Isabelle [corrected to Vande Broek, Isabelle].

29.

The involvement of osteopontin and its receptors in multiple myeloma cell survival, migration and invasion in the murine 5T33MM model.

Caers J, Günthert U, De Raeve H, Van Valckenborgh E, Menu E, Van Riet I, Van Camp B, Vanderkerken K.

Br J Haematol. 2006 Feb;132(4):469-77.

PMID:
16412019
30.

Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model.

Menu E, Jernberg-Wiklund H, Stromberg T, De Raeve H, Girnita L, Larsson O, Axelson M, Asosingh K, Nilsson K, Van Camp B, Vanderkerken K.

Blood. 2006 Jan 15;107(2):655-60. Epub 2005 Jul 26. Erratum in: Blood. 2011 Mar 24;117(12):3476.

PMID:
16046527
31.

Targeting an MMP-9-activated prodrug to multiple myeloma-diseased bone marrow: a proof of principle in the 5T33MM mouse model.

Van Valckenborgh E, Mincher D, Di Salvo A, Van Riet I, Young L, Van Camp B, Vanderkerken K.

Leukemia. 2005 Sep;19(9):1628-33.

PMID:
16015389
32.

The 5T2MM murine model of multiple myeloma: maintenance and analysis.

Vanderkerken K, Asosingh K, Willems A, De Raeve H, Couck P, Gorus F, Croucher P, Van Camp B.

Methods Mol Med. 2005;113:191-205.

PMID:
15968104
33.

Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression.

Asosingh K, De Raeve H, de Ridder M, Storme GA, Willems A, Van Riet I, Van Camp B, Vanderkerken K.

Haematologica. 2005 Jun;90(6):810-7.

34.

[Open letter to the Presidents of the Brussels Université Libre and the Brussels Vrije Universiteit].

Van Camp B, de Maret P.

Rev Med Brux. 2005 Mar-Apr;26(2):69. French. No abstract available.

PMID:
15945417
35.

Catheter tip position as a risk factor for thrombosis associated with the use of subcutaneous infusion ports.

Caers J, Fontaine C, Vinh-Hung V, De Mey J, Ponnet G, Oost C, Lamote J, De Greve J, Van Camp B, Lacor P.

Support Care Cancer. 2005 May;13(5):325-31. Epub 2004 Nov 5.

PMID:
15538639
36.

Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model.

Van Valckenborgh E, Croucher PI, De Raeve H, Carron C, De Leenheer E, Blacher S, Devy L, Noël A, De Bruyne E, Asosingh K, Van Riet I, Van Camp B, Vanderkerken K.

Am J Pathol. 2004 Sep;165(3):869-78.

37.

Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma.

Bakkus MH, Bouko Y, Samson D, Apperley JF, Thielemans K, Van Camp B, Benner A, Goldschmidt H, Moos M, Cremer FW.

Br J Haematol. 2004 Sep;126(5):665-74.

PMID:
15327517
38.

Myeloma cells (5TMM) and their interactions with the marrow microenvironment.

Menu E, Asosingh K, Van Riet I, Croucher P, Van Camp B, Vanderkerken K.

Blood Cells Mol Dis. 2004 Sep-Oct;33(2):111-9. Review.

PMID:
15315788
39.

Part of the multiple myeloma-associated microvessels is functionally connected to the systemic circulation: a study in the murine 5T33MM model.

De Raeve HR, Asosingh K, Wisse E, Van Camp B, Van Marck E, Vanderkerken K.

Virchows Arch. 2004 Oct;445(4):389-95. Epub 2004 Jun 30.

PMID:
15232744
40.

Angiogenesis and the role of bone marrow endothelial cells in haematological malignancies.

De Raeve H, Van Marck E, Van Camp B, Vanderkerken K.

Histol Histopathol. 2004 Jul;19(3):935-50. doi: 10.14670/HH-19.935. Review.

PMID:
15168356
41.

Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity.

Asosingh K, De Raeve H, Menu E, Van Riet I, Van Marck E, Van Camp B, Vanderkerken K.

Blood. 2004 Apr 15;103(8):3131-7. Epub 2003 Nov 26.

PMID:
15070695
42.

Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor.

Vande Broek I, Asosingh K, Allegaert V, Leleu X, Facon T, Vanderkerken K, Van Camp B, Van Riet I.

Leukemia. 2004 May;18(5):976-82.

PMID:
14999296
43.

Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model.

Menu E, Kooijman R, Van Valckenborgh E, Asosingh K, Bakkus M, Van Camp B, Vanderkerken K.

Br J Cancer. 2004 Mar 8;90(5):1076-83.

44.

Multiple myeloma biology: lessons from the 5TMM models.

Vanderkerken K, Asosingh K, Croucher P, Van Camp B.

Immunol Rev. 2003 Aug;194:196-206. Review.

PMID:
12846816
45.

Delayed in vivo disease progression is associated with high proportions of CD45+ myeloma cells in the 5T2MM murine model.

Asosingh K, Willems A, Van Riet I, Van Camp B, Vanderkerken K.

Cancer Res. 2003 Jun 15;63(12):3019-20.

46.

Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation.

Schots R, Kaufman L, Van Riet I, Ben Othman T, De Waele M, Van Camp B, Demanet C.

Leukemia. 2003 Jun;17(6):1150-6.

PMID:
12764383
47.
48.

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.

Croucher PI, De Hendrik R, Perry MJ, Hijzen A, Shipman CM, Lippitt J, Green J, Van Marck E, Van Camp B, Vanderkerken K.

J Bone Miner Res. 2003 Mar;18(3):482-92.

49.

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.

Croucher PI, Shipman CM, Van Camp B, Vanderkerken K.

Cancer. 2003 Feb 1;97(3 Suppl):818-24.

50.

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.

Vanderkerken K, De Leenheer E, Shipman C, Asosingh K, Willems A, Van Camp B, Croucher P.

Cancer Res. 2003 Jan 15;63(2):287-9.

Supplemental Content

Loading ...
Support Center